PIII (PIII) revenue breakdown
By product, Capitated Revenue is the largest at 98% of fiscal 2025 revenue, growing 47% a year over 6 years.
Revenue by product
Fiscal years, as PIII reports them in its 10-K filings; fiscal 2025 total $1.5B.
| Products | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| Capitated Revenue | $139M | $481M | $568M | $1.0B | $1.3B | $1.5B | $1.4B | 98% |
| Health Care Incentive Fees | — | — | — | $238,000 | $573,000 | $356,000 | $16M | 1% |
| Health Care Coordination Management Fees | — | — | — | $8M | $8M | $11M | $11M | 1% |
| Health Care Clinical Fees Insurance Revenue | — | — | — | $6M | $5M | $6M | $3M | 0% |
| Other patient service revenue | $6M | $10M | $11M | — | — | — | — | — |
| Shared risk revenue | — | — | — | $351,000 | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for PIII.
Open PIII in InvestinglyQuestions
Where does PIII make its money?
In fiscal 2025, by product: Capitated Revenue $1.4B, Health Care Incentive Fees $16M, Health Care Coordination Management Fees $11M, Health Care Clinical Fees Insurance Revenue $3M.
From PIII's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.